公开(公告)号：US20230071675A1

公开(公告)日：2023-03-09

申请号：US17663749

申请日：2022-05-17

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Adam Kenneth CHARNLEY ,  Michael G DARCY ,  Jason W. DODSON ,  Xiaoyang DONG ,  Terry V. HUGHES ,  Jianxing KANG ,  Lara LEISTER ,  Yiqian LIAN ,  Yue LI ,  John F. MEHLMANN ,  Neysa NEVINS ,  Joshi M. RAMANJULU ,  Joseph J. ROMANO ,  Gren Z. WANG ,  Guosen YE ,  Daohua ZHANG

IPC: C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D487/22 ,  C07D493/10 ,  C07D498/18 ,  C07F9/6558

Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

公开(公告)号：US20220112174A1

公开(公告)日：2022-04-14

申请号：US17492978

申请日：2021-10-04

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Edward BRNARDIC ,  Michael BURY ,  Rodolfo CADILLA ,  Jon COLLINS ,  Yu GUO ,  Anthony HANDLON ,  Huijie LI ,  Yue LI ,  Daniel PAONE ,  Christie SCHULTE ,  Barry SHEARER ,  Guosen YE ,  Maben YING ,  Huichang ZHANG

IPC: C07D401/14

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.